{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/MDCX"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MDCX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MDCX\",,,,,undefined,":{"symbol":"MDCX","market":"US","secType":"STK","nameCN":"Medicus Pharma Ltd.","latestPrice":2.79,"timestamp":1749758400000,"preClose":2.67,"halted":0,"volume":184173,"hourTrading":{"tag":"盘后","latestPrice":2.84,"preClose":2.79,"latestTime":"17:52 EDT","volume":1965,"amount":5511.470514000001,"timestamp":1749765139332},"delay":0,"floatShares":6964800,"shares":15832737,"eps":0,"marketStatus":"Post-Mkt","change":0.12,"latestTime":"06-12 18:46:20 EDT","open":2.69,"high":2.825,"low":2.6103,"amount":503931.400005,"amplitude":0.080412,"askPrice":2.85,"askSize":300,"bidPrice":2.66,"bidSize":100,"shortable":0,"etf":0,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1749772800000},"marketStatusCode":4,"adr":0,"listingDate":1731560400000,"exchange":"NASDAQ","adjPreClose":2.67,"preHourTrading":{"tag":"盘前","latestPrice":2.6,"preClose":2.67,"latestTime":"09:26 EDT","volume":1511,"amount":3940.5598671999996,"timestamp":1749734763856},"postHourTrading":{"tag":"盘后","latestPrice":2.84,"preClose":2.79,"latestTime":"17:52 EDT","volume":1965,"amount":5511.470514000001,"timestamp":1749765139332},"volumeRatio":0.583456},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MDCX\",,,,,undefined,":{"symbol":"MDCX","floatShares":6964800,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.583456,"shares":15832737,"dividePrice":0,"high":2.825,"amplitude":0.080412,"preClose":2.67,"low":2.6103,"week52Low":1.8,"pbRate":"--","week52High":8.94,"institutionHeld":0,"latestPrice":2.79,"committee":-0.5,"eps":0,"divideRate":0,"volume":184173,"delay":0,"ttmEps":0,"open":2.69,"prevYearClose":2.43,"prevWeekClose":2.76,"prevMonthClose":2.55,"prevQuarterClose":3.72,"fiveDayClose":2.71,"twentyDayClose":6.32,"sixtyDayClose":3.08},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/MDCX\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MDCX\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2542151667","title":"Medicus Pharma Ltd. Announces Binding Letter of Intent to Acquire UK Biotech Firm Antev Ltd","url":"https://stock-news.laohu8.com/highlight/detail?id=2542151667","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542151667?lang=en_us&edition=fundamental","pubTime":"2025-06-12 19:31","pubTimestamp":1749727878,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. has announced the signing of a binding letter of intent to acquire Antev Ltd., a UK-based late clinical stage biotech company. Antev is developing Teverelix, a next-generation GnRH antagonist aimed at providing a first-in-market treatment for cardiovascular high-risk advanced prostate cancer patients and those experiencing first acute urinary retention relapse episodes due to an enlarged prostate. This acquisition marks a significant step for Medicus Pharma in expanding its portfolio and strengthening its position in the biotech industry.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via Newsfile  on June 12, 2025, and is solely res","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250612:nNDL6bRCRk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MDCX"],"gpt_icon":0},{"id":"2542333762","title":"Medicus Pharma Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2542333762","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542333762?lang=en_us&edition=fundamental","pubTime":"2025-06-09 22:47","pubTimestamp":1749480420,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MDCX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 09, 2025 10:47 ET (14:47 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX"],"gpt_icon":0},{"id":"2542056389","title":"Medicus Pharma Ltd. Submits Product Development Plan to FDA for Treating Squamous Cell Carcinoma in Horses with D-MNA Patch","url":"https://stock-news.laohu8.com/highlight/detail?id=2542056389","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542056389?lang=en_us&edition=fundamental","pubTime":"2025-06-09 19:31","pubTimestamp":1749468665,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. has announced the submission of a comprehensive product development plan to the Food and Drug Administration  to treat external squamous cell carcinoma  in horses. This plan involves the use of a novel Doxorubicin-containing microneedle array  patch, which in December 2024 received a Minor Use in Major Species Designation . The submission aims to seek the FDA's concurrence under the MUMS designation, advancing the company's efforts in veterinary oncology. This development is part of Medicus Pharma's broader initiative to innovate treatment options in veterinary medicine.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via Newsfile  on","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250609:nNDL4VtW0k:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MDCX"],"gpt_icon":0},{"id":"2541300581","title":"Medicus Pharma Ltd. Dismisses EisnerAmper Amid Concerns Over \"Going Concern\" Status","url":"https://stock-news.laohu8.com/highlight/detail?id=2541300581","media":"Reuters","labels":["executive","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541300581?lang=en_us&edition=fundamental","pubTime":"2025-06-06 04:06","pubTimestamp":1749153971,"startTime":"0","endTime":"0","summary":"**Medicus Pharma Ltd. Announces Change in Certifying Accountants Amidst Financial Concerns** June 5, 2025 - Medicus Pharma Ltd. has announced the dismissal of EisnerAmper LLP as its independent registered public accounting firm, following a recommendation by the company's audit committee and approval by the board of directors. The decision comes after EisnerAmper raised concerns about the company's ability to continue as a going concern due to negative cash flows and operating losses. EisnerAmper's report for the fiscal year ending December 31, 2024, highlighted substantial doubt about Medicus Pharma's financial stability, although it did not issue an adverse opinion or disclaimer. Despite these concerns, there were no disagreements between the company and EisnerAmper on accounting principles or practices. KPMG LLP has been appointed as the new independent registered public accounting firm, with EisnerAmper authorized to fully cooperate with the transition. This change follows disclosu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nNDL3r0Zlj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Medicus Pharma Ltd. Dismisses EisnerAmper Amid Concerns Over \"Going Concern\" Status","news_tag":"executive,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MDCX"],"gpt_icon":0}],"pageSize":4,"totalPage":12,"pageCount":1,"totalSize":48,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MDCX\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MDCX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MDCX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":3,"updateTime":1744689600000}}}